Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Theravectys manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 2 pending office actions. These actions are distributed across 2 distinct art units, which suggests that the company's research and development efforts are spanning multiple technical sub-specialties within the broader biotechnology field. For practitioners, this diversification across 2 art units means that the portfolio is subject to different sets of technical classification standards and examination guidelines.
The prosecution of these matters is handled by 2 distinct examiners. KIM, YUNSOO is the busiest examiner for the portfolio, holding 1 busiest examiner pending action. This means that the workload is evenly split, with KIM, YUNSOO responsible for half of the 2 pending office actions. For the applicant, this distribution across 2 examiners and 2 art units means they must manage two separate prosecution tracks, each with its own set of examiner expectations and technical standards. This arrangement provides the company with a diversity of examiner perspectives, reducing the risk of the entire portfolio being impacted by the preferences of a single official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YUNSOO | 1 | 65.9% | +34.3% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549286 | LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST | KIM, YUNSOO | — |
| 18005146 | SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS | CHEN, STACY BROWN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18549286 | LENTIVIRAL VECTORS TARGETING ANTIGENS TO MHC-II PATHWAY AND INDUCING PROTECTIVE CD8+ AND CD4+ T-CELL IMMUNITY IN A HOST | KIM, YUNSOO | 1641 | §103§112DP | Non-Final OA | — | Pending | Sep 06, 2023 |
| 18005146 | SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS | CHEN, STACY BROWN | 1672 | §102§103§112DP | Non-Final OA | — | Pending | Jan 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial